I'm LongbridgeAI, I can summarize articles.Hob Biotech released its 2024 annual report, with operating revenue of 402 million yuan, a year-on-year increase of 2.01%; net profit attributable to the parent company was 36.8038 million yuan, a year-on-year decrease of 22.24%. The net profit excluding non-recurring gains and losses was 35.8756 million yuan, a year-on-year decrease of 17.16%. The company plans to distribute a cash dividend of 3.0 yuan for every 10 shares to all shareholders. Affected by macroeconomic fluctuations, market demand has slowed, resulting in a narrowing increase in main business revenue. During the reporting period, the company increased its clinical expense investment for the desensitizing drug "Otuoke," leading to a decline in net profit
According to the Zhitong Finance APP, Hob Biotech (688656.SH) released its annual report for 2024, reporting an operating income of 402 million yuan for the year, a year-on-year increase of 2.01%; the net profit attributable to shareholders of the listed company was 36.8038 million yuan, a year-on-year decrease of 22.24%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 35.8756 million yuan, a year-on-year decrease of 17.16%; basic earnings per share were 0.59 yuan/share. It plans to distribute a cash dividend of 3.0 yuan (including tax) for every 10 shares to all shareholders.
During the reporting period, affected by fluctuations in the macroeconomic environment, the growth rate of market terminal demand temporarily slowed down, leading to a narrowing increase in main business revenue, with operating income growing by 2.01% compared to the same period last year. The company achieved a net profit attributable to shareholders of the listed company and a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses, which decreased by 22.24% and 17.16% year-on-year, mainly due to the company's increased investment in clinical-related expenses for the desensitization drug "Otuoke" during the reporting period, although this business is still in the initial investment stage and requires time for revenue growth and development; the share-based payment expenses for equity incentives increased compared to the same period last year; with the implementation of fundraising projects in 2024, the company increased corresponding depreciation and amortization expenses; the fundraising projects are basically completed in 2024, and the income from idle raised funds invested in bank wealth management products decreased compared to the same period last year